EN | RU
EN | RU

Help Support

Back

Influence of dupilumab on work productivity in atopic dermatitis people

Influence of dupilumab on work productivity in atopic dermatitis people Influence of dupilumab on work productivity in atopic dermatitis people
Influence of dupilumab on work productivity in atopic dermatitis people Influence of dupilumab on work productivity in atopic dermatitis people

A study (Dutch BioDay Registry) investigated the influence of dupilumab therapy on presenteeism, absenteeism, and associated costs in a large multi-centre cohort of 218 adults suffering from atopic dermatitis. 

See All

Key take away

In adults with difficult-to-treat atopic dermatitis in daily practice, dupilumab therapy remarkably improved work productivity and declined the associated costs.

Background

A study (Dutch BioDay Registry) investigated the influence of dupilumab therapy on presenteeism, absenteeism, and associated costs in a large multi-centre cohort of 218 adults suffering from atopic dermatitis. 

Method

The study recruited atopic dermatitis people who were given dupilumab therapy. With the aid of Work Productivity and Activity Impairment questionnaire, estimation of work presenteeism, absenteeism, and associated costs at the baseline and during the follow-up was done.

Result

At week 52, a considerable drop in total work impairment and median weekly productivity losses was reported when compared to the baseline in dupilumab recipients, as shown in Table 1:


Conclusion

A sustained and rapid decline in work presenteeism, absenteeism, and related costs were noted in individuals having atopic dermatitis and managed with dupilumab in daily practice for about 52 weeks. 

Source:

Acta dermato-venereologica.

Article:

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

Authors:

Lieneke F M Ariëns et al.

Comments (0)

Recommendations

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: